Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Abstract 7577: Advancing the science, practice and impact of COE.
Ashing, Kimlin, Zeigler-Johnson, Charnita M. , Bawa, Lisa Carter, Nolan, T. S., Phillips, E. P. , Odedina, Folakemi T., Zeigler-Johnson, Charnita M , Thompson, Hayley S. , Rhoads, Kim F. , Barrett, Nadine J. , Carter‐Harris, Lisa , Nolan, Timiya S. , Baskin, Monica L. , Sheppard, Vanessa B. , Ford, Marvella Elizabeth , McNeill, Lorna Haughton.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7577-7577

10.1158/1538-7445.am2026-7577 Get It

Abstract Introduction: COE has become the gold standard in addressing health disparities. COE’s value is emphasized by NIH and leading cancer-related organizations e.g., AACR. The Alliance for COE (The Alliance) mission is to advance the art, science, and impact of COE; promote community health and wellness; and reduce cancer burden and disparities. Methods: This abstract builds on the Alliance’s Science of Community Outreach and Engagement (SoCOE) Conference a NCI R13 funded series. SoCOE Conference is organized by 10 NCI-designated Cancer Centers to provide a platform for COE academic-clinical-policy-community stakeholders to share best practices for solution-focused community responsive cancer prevention, diagnostics, therapeutics and survivorship research and practice. Results: > 500 researchers, clinicians, policymakers, healthcare administrators, with >12% being survivors and/or advocates, participated in our SoCOE Conferences. The delegates’ recommendations are: Decentralize who/entities that hold all the power in science and clinical research (trials). Communities hold valuable, necessary wisdom and resources to inform and guide science Include multisectoral partners early and always Community capacity building and compensation with gratitude Mentoring of junior COE researchers, clinicians, policymakers, healthcare administrators, survivors and advocates with humility is a must Develop virtual communities to share best practices across cancer centers and within regions Develop working groups to identify and explore commonalities across COE work in rural/urban, diverse/homogenous spaces Publish Science of COE papers on various topics related to COE Frameworks and evidenced-solutions Provide community reports on best practice guide that can be widely available to be shared locally and in-person, and digitally Partner and learn from COE teams working with other cultural/ethnic groups Attend to, measure and remedy societal/social drivers of health disparities that mirror barriers to care, and research engagement and participation. Discussion: Informed by our community advisory boards and the findings for our SoCOE Conferences, we present the pillars of the Alliance to tackle population cancer burden and disparities: Training future COE leaders/advocates, Advocating for public health policies/guidelines, Increasing access to cancer prevention and care that will also increase access to studies, Engaging and partnering with multisectoral stakeholders and communities, Building community capacity, Advancing COE science through catchment-relevant research, and Leading bi-directional communication and information and resource sharing between catchment area communities and cancer centers. The expectation and impact of COE can only be achieved if COE teams are valued, supported cancer center members with community advisory boards and community as cancer centers’ priority population. Citation Format: Kimlin Ashing, CHARNITA ZEIGLER-JOHNSON, Hayley S. Thompson, Kim Rhoads, Nadine Barrett, Lisa Carter Bawa, Timiya S. Nolan, Monica Baskin, Vanessa B. Sheppard, Marvella E. Ford, Erica Phillips, Lorna H. McNeill, Folakemi T. Odedina. Advancing the science, practice and impact of COE [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7577.
Abstract 1441: Whole-slide image and clinical feature integration for superior prostate cancer risk stratification.
Johnson, Justin M. , Ebare, Kingsley

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1441-1441

10.1158/1538-7445.am2026-1441 Get It

Abstract Background: Prostate cancer remains one of the most common malignancies in men, with significant heterogeneity in clinical outcomes. Early and accurate diagnosis and risk stratification is crucial for effective treatment and improved outcomes. Although Gleason score is an established risk stratification tool, it does not fully explain outcome variability. We present a multimodal deep-learning framework that integrates attention-based whole-slide image (WSI) features with a clinical variable (Age) to predict survival in patients with prostate adenocarcinoma. Design: Clinical data and WSI for 500 patients with prostate adenocarcinoma were obtained from TCGA-PRAD. Clinical data were parsed for recurrence or progression (RoP) events and age. RoP was used as the outcome label, and age was used as a patient feature. Diagnostic WSI tumor regions were annotated and tiled at 224×224 pixels using QuPath (Bankhead Sci Rep 2017). Tile embeddings were extracted with UNI2-h (Mahmood Nat Med 2025). An end-to-end machine learning pipeline was developed to aggregate tile embeddings into slide-level embeddings using Clustering-Constrained Attention Multiple Instance Learning (CLAM) and predict RoP (Lu Nat Biomed 2021). A second pipeline used a Gleason score-trained binary cross entropy (BCE) model to predict RoP in the same patients. Three models were evaluated: WSI-only CLAM model, WSI+age CLAM model, and Gleason-only BCE model. All models were trained and evaluated using 5-fold stratified cross-validation. Each fold was repeated 3 times with independent random initialization. AUROC was averaged across all folds and runs per model. Standard deviation was also computed. Model performance was compared using Friedman’s test, with post hoc pairwise comparisons by Wilcoxon signed-rank test. Results: The Gleason BCE model underperformed (AUROC 0.67 ± 0.07). Both WSI-based models outperformed the Gleason BCE model, achieving AUROC 0.76 ± 0.02 (without age), and AUROC 0.76 ± 0.01 (with age). AUROCs were significantly different by Friedman’s test (p = 0.0224) and showed a trend toward significance in post-hoc comparison between WSI and Gleason-based approaches (p = 0.06). Conclusion: AI models using WSI-derived features, with or without basic clinical context, outperformed traditional Gleason score for recurrence risk prediction in prostate cancer. These findings support the integration of digital pathology and AI into routine prognostic assessment for prostate cancer. Future work will focus on including additional patients, clinical variables, and multi-class prognostic labels to expand prognostic prediction beyond RoP. Citation Format: Justin Johnson, Kingsley Ebare. Whole-slide image and clinical feature integration for superior prostate cancer risk stratification [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1441.
Abstract 7322: Vav1 promotes pancreatic tumor cell invasion via GLS1-dependent glutamine metabolism
Gutierrez-Ruiz, Omar L. , Johnson, Katherine M., Chianis, Ella Rose D. , Chen, Jing, Bittner, Alex, Zahm, Adam M. , Chhoda, Ankit , Hitosugi, Taro, McNiven, Mark A., Gedik, Mustafa Emre , Johnson, Katherine M., Bittner, Alex, Hitosugi, Taro , McNiven, Mark A. , Razidlo, Gina L.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7322-7322

10.1158/1538-7445.am2026-7322 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy due in part to metabolic rewiring and a high rate of metastasis. Pancreatic tumors are particularly dependent upon glutamine (Gln) as a nutrient source for multiple metabolic pathways. To adapt to low levels of glutamine, PDAC cells upregulate the Rac1 dependent process of macropinocytosis, which internalizes extracellular macromolecules to scavenge them as a glutamine source. The proto oncogene Vav1 is an activator of the potent Rac/Cdc42 signaling cascades that regulate actin dynamics. While Vav1 is normally restricted to hematopoietic cells, Vav1 expression is significantly increased in PDAC, with high Vav1 correlating with worse overall survival. Here we uncover a novel Vav1 mediated regulation of glutamine metabolism in PDAC cells. While Vav1 is a potent activator of Rac1, surprisingly, Vav1 expression inhibited macropinocytosis in PDAC cells. Intriguingly, genomic and metabolomic analysis revealed that high Vav1 expression correlates with increased dependence on glutamine and glutamate (Glu) metabolism. Indeed, Vav1 dependent macropinocytosis was rescued by cell permeable glutamate, confirming disrupted Gln/Glu balance in Vav1 knockdown cells. RPPA screening indicated a Vav1 dependent effect on glutaminase 1 (GLS1, KGA isoform), which converts glutamine to glutamate. Mechanistically, we discovered that Vav1 modulates GLS1 localization to the mitochondria through regulation of GLS1 posttranslational modification. Disrupting GLS1 localization by deleting its mitochondrial targeting motif phenocopied loss of Vav1 in reducing the invasive potential of tumor cells. Investigation of Vav1 dependent metabolic consequences showed that knockdown of Vav1 alters 13C Gln derived metabolic flux into the TCA cycle, as well as a deficiency in the level of the antioxidant glutathione (GSH), which utilizes glutamate for its synthesis. Consequently, targeting Vav1 resulted in increased levels of cellular and mitochondrial reactive oxygen species (ROS) and increased sensitivity to lipid peroxidation. Notably, dual targeting of both glucose and glutamine pathways showed significant synergistic effects on cellular viability in Vav1 expressing cells. Here we established a new tumor promoting role for Vav1 via Gln/Glu regulation and uncover a novel subcellular regulation of mitochondrial glutamine metabolism. Our findings establish Vav1 as a critical regulator of metabolic rewiring in PDAC and orchestrates glutamine metabolism by controlling the KGA isoform of GLS1 mitochondrial localization. Importantly, Vav1 functions as a signaling adapter in glutamine metabolism, providing a potential therapeutic vulnerabilities for PDAC patients with high Vav1 expression. Citation Format: Mustafa Emre Gedik, Omar L. Gutierrez-Ruiz, Katherine M. Johnson, Ella Rose D. Chianis, Jing Chen, Alex Bittner, Adam Zahm, Ankit Chhoda, Taro Hitosugi, Mark A. McNiven, Gina Razidlo. Vav1 promotes pancreatic tumor cell invasion via GLS1-dependent glutamine metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7322.
Abstract 2611: Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy.
Tran, Nguyen H., Hirdler, Jacob, Antony, Ajith , Torbenson, Michael S., Thompson, Scott M. , Halfdanarson, Thor R., Jin, Zhaohui, Fonkoua, Lionel Aurelien Kankeu, Washburn, Leslie, Revzin, Alexander , Dong, Haidong, Jatoi, Aminah , Borad, M., Bekaii-Saab, T., Gores, Gregory J., Roberts, Lewis R. , Johnson, Geoffrey B., Goenka, Ajit H. , Roberts, Lewis R , Tran, Nguyen H. , Hirdler, Jacob B. , Teske, Jacob J. , Venkatesh, Sudhakar K. , Mahipal, Amit , Torbenson, Michael , Halfdanarson, Thor R, Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , McWilliams, Robert R. , Babiker, Hani M. , Borad, Mitesh J. , Gores, Gregory J. , Johnson, Geoffrey B

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2611-2611

10.1158/1538-7445.am2026-2611 Get It

Abstract Prostate-specific membrane antigen (PSMA) is highly expressed in tumor-associated neovasculature in hepatocellular carcinoma (HCC), highlighting its promise as a theranostic target. This prospective study aimed to evaluate the utility of novel biomarkers derived from PSMA positron emission tomography computed tomography (PET/CT) to assess treatment response in advanced HCC patients (pts) receiving first line immune checkpoint inhibitors (ICI). Methods: This study (NCT05176223) enrolled unresectable, advanced HCC pts eligible for first-line ICI (atezolizumab/bevacizumab [A/B] or durvalumab/tremelimumab [D/T]) with measurable disease according to RECIST criteria. Primary endpoints: progression-free survival (PFS) per RECIST 1.1 and mRECIST; overall survival (OS); and best overall response. The survival distribution was estimated using the Kaplan-Meier method. Observed agreement is defined as the proportion of pts whose responses, as classified by PET/CT or CT, were concordant. Weighted kappa and Cohen’s kappa were used to quantify the strength of agreement between PET/CT and CT. Pts completed up to five 68Ga-PSMA PET/CT scans and blood collections. Results: Twenty-six pts were enrolled (25 evaluable) between Oct 2022 and Nov 2024. Median follow up was 22.1 months (m) (Q1, Q3: 14.5-23.7). Median age 68 yrs, 72% male, 88% White, 68% Child-Pugh [CP] A, 32% CP B, 32% Barcelona Clinic Liver Cancer [BCLC] stage B, 68% BCLC stage C, 36% with microvascular invasion; 56% received A/B and 40% received D/T treatment. PSMA was positive in 96% of pts at baseline with median SUVmax 14.3 (range 5.1-40.5) and median background liver SUVmax 3.9 (range 2.1-6.8). Median (95%CI) PFS was 5.6 m (4.6-12.5) by both RECIST and mRECIST. Median (95%CI) OS was 18.6 m (7.2-not estimable), with 56% deceased. The observed agreement between PET/CT adapted PERCIST criteria compared to RECIST and mRECIST in determining the best response was 46% and 50% and weighted kappa of 0.63 (95% CI: 0.37-0.90) and 0.66 (0.41-0.92), respectively. Observed agreement between PERCIST compared to RECIST and mRECIST for responders’ assessment was 67% and 71% with Cohen’s kappa of 0.36 (0.03-0.68) and 0.43 (0.11-0.76), respectively. Conclusion: In this cohort, PSMA PET/CT avidity was observed in all but one pt with advanced HCC, each demonstrating moderate to high SUVmax values. Median OS and PFS were consistent with outcomes reported in clinical trials. Response assessment using 68Ga-PSMA PET/CT according to PERCIST criteria showed good concordance with both RECIST and mRECIST standards. Analysis of immune biomarkers is ongoing. Citation Format: Nguyen H. Tran, Jacob Hirdler, Ajith Antony, Jacob Teske, Sudhakar K. Venkatesh, Amit Mahipal, Michael S. Torbenson, Scott M. Thompson, Thor R. Halfdanarson, Zhaohui Jin, Lionel Aurelien Kankeu Fonkoua, Leslie A. Washburn, Alexander Revzin, Haidong Dong, Robert R. Mcwilliams, Aminah Jatoi, Hani M. Babiker, Mitesh J. Borad, Tanios Bekaii-Saab, Gregory J. Gores, Lewis R. Roberts, Geoffrey B. Johnson, Ajit H. Goenka. Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2611.
Health Care Use and Outcomes Among Participants Enrolled in the Mayo Clinic Primary Care House Call Program: A Case-Control Study
Takahashi, Paul Y. , Sohn, Bonnie C. , Verdoorn, Brandon P. , Chandra, Anupam , Mohammad, Natalie F, Philpot, Lindsey M. , Havyer, Rachel D. , Roellinger, Daniel , Johnson, Matthew G. , West, Jennifer, Hanson, Gregory J. , Garza, Maria D. Mendoza De la, Mendoza De la Garza, Maria D, Philpot, Lindsey M , Takahashi, Paul , Mohammad, Natalie F. , Hanson, Gregory J., Garza, Maria Mendoza de la

Mayo Clinic

Journal of Primary Care & Community Health | April 3, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261432120 | PMID 41928581 Get It

Introduction/Objectives: House call programs provide care for homebound patients. We conducted a case-control study to compare hospitalization and/or emergency department (ED) use by patients enrolled in a primary care house call program versus ambulatory (community-dwelling) patients. Methods: Program enrollees (cases) were matched by age and self-reported gender to community-dwelling patients (controls). The primary exposure was the combination of hospitalization and/or ED visits for 1 year before the index date (October 1, 2024). We used unadjusted and adjusted conditional logistic regression to determine differences in health care use. Results: We identified 26 cases (median [range] age, 84 [66-98] years; 16 [62%] female) and 130 controls. All cases had 4 or more chronic diseases, as compared with 87 (67%) of controls ( P = .003). A higher proportion of cases than controls had previous hospitalization and/or ED visits (84.6% vs 27.7%; P < .001). After adjusting for the number of chronic illnesses, no differences in previous hospitalization and/or ED use were identified between groups. Conclusions: Cases had more chronic illnesses and more hospitalizations and/or ED visits than community-dwelling controls. The comorbid health burden of participants in the house call program drove greater health care use and justifies a higher level of care for this medically complex patient population.
Estimating Blood Volume Loss With Wireless, Wearable Ultrasound: A Pilot Investigation
Kenny, Jon‐Émile S. , Savery, Tracy, Lachner-Piza, Daniel, Eibl, Andrew M., Eibl, Joseph K. , Vungarala, Soumya , Dietz, Niki M., Kim, Chul-Ho, Johnson, Bruce D, Hebscher, Melissa , Atwi, Sarah , Piza, Daniel Lachner , Johnson, Bruce D.

Mayo Clinic

Military Medicine | April 2, 2026 | Volume: 191 | Issue: Supplement_1 | Pages: 386-392

10.1093/milmed/usag109 | PMID 42560273 Get It

Abstract Introduction Detecting and estimating blood volume loss are important for the diagnosis and management of life-threatening hemorrhage. There is a direct relationship between percent blood volume loss (BVL%) and falling in stroke volume (SV); furthermore, there is a direct relationship between diminishing SV and the corrected flow time of the carotid artery (ccFT). Therefore, we hypothesized that change in ccFT (ccFTΔ) would directly relate with BVL% in a phlebotomy paradigm. Materials and Methods A prospective, convenience sample of healthy volunteers was studied. Volunteers underwent blood donation protocol in a physiology lab. A wireless, wearable Doppler ultrasound system monitored ccFT during blood donation. Traditional vital signs were also measured throughout. The relationship between traditional vital signs as well as ccFTΔ were compared to BVL% using 2 mixed linear regression models. Results Data from 20 subjects and blood donations comprising 46,123 cardiac cycles are included. On average 413.5 ± 39 mL of blood were drawn representing 8.6 ± 1.6% BVL%. There was a significant and strong linear relationship between BVL% and ccFTΔ during blood draw with the regression slope demonstrating that for every 1 ms reduction in ccFT there was a 0.4% reduction in blood volume. Conclusions In healthy subjects and when blood loss is the sole mechanism for falling SV, we estimate that for every 1 ms reduction in ccFT, there is an approximate 0.4 BVL%. Validation of these results in patients with traumatic hemorrhage is underway.
Upper Airway Anesthesia Techniques and Sedation Strategies for Awake Fiberoptic Intubation: A Novel Workshop for Anesthesia Residents
Ellis, Megan , Ivare, Hali N. , Stites, A. C., Damon, Aaron , Johnson, Jimmy A. , Huang, Jeffrey , Peterson, Hali N. , Ellis, Megan M , Stites, Andrew J , Damon, Aaron C

Mayo Clinic

MedEdPORTAL | April 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11590 | PMID 41939796 Get It

Under-recognized Cardiac Disease Burden in DDX3X Syndrome: Spectrum of Cardiovascular Abnormalities and Longitudinal Outcomes
Dhamija, Radhika, Rada, Lauren, Fittanto, Sarah , Johnson, Jonathan N. , Hagler, Donald J. , Stephens, Elizabeth H. , Gallego-Navarro, Carlos , Theis, Jeanne L. , Dhamija, Radhika , Schimmenti, Lisa A. , Thompson, Whitney S. , Niaz, Talha

Mayo Clinic

No container title available | April 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9059706/v1 Get It

Abstract Background DDX3X- syndrome is a rare neurodevelopmental disorder characterized by varying degrees of intellectual disability, predominantly affecting females. We present an institutional cohort supplemented by a systematic literature review, expanding the cardiovascular phenotype of DDX3X- syndrome. Methods We conducted a retrospective chart review of patients diagnosed with DDX3X -syndrome at Mayo Clinic. Additionally, we performed a systematic literature review to identify studies reporting cardiovascular abnormalities in patients with DDX3X -syndrome. Results A total of 200 patients with DDX3X -syndrome were analyzed, comprising 14 patients from our institutional cohort and 186 patients identified through a systematic review of 9 published studies. Our institutional cohort included 14 patients (12 females and 2 males) from 13 unrelated families diagnosed with DDX3X -syndrome, at a median age of 4.5 years (IQR 1.2–9.5). Echocardiogram was performed on nine patients, and cardiovascular abnormalities were found in 7 out of 9 patients who underwent echocardiography (78%), two of whom had major congenital heart defect (CHD) requiring surgical intervention. At the time of assessment, 13 individuals were still alive, while one had died at age six due to extracardiac complications. The systematic review included 9 studies involving 186 patients, of whom 32 (17.4%, 25 females and 7 males) had reported cardiovascular abnormalities, ranging from simple CHDs to more complex defects. Conclusion DDX3X -syndrome carries a significant cardiovascular burden, which is possibly higher than previously reported, including complex congenital heart disease requiring surgical repair. A thorough cardiovascular assessment, including an electrocardiogram and echocardiogram, should be universally recommended for all patients at the time of diagnosis.
American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2025 Guidelines for the Management of Infectious and Inflammatory Lesions of the Breast
Mitchell, Katrina B. , Snider, Howard C., Allison, Kimberly H. , Pass, Helen A. , Boolbol, Susan K., Johnson, Nathalie , Yao, Katharine , Valente, Stephanie A. , Fowler, Amy M. , Boughey, Judy C.

Mayo Clinic

JAMA Surgery | April 1, 2026 | Volume: 161 | Issue: 6 | Pages: 637

10.1001/jamasurg.2026.0613 | PMID 41920556 Get It

Importance The management of infectious and inflammatory lesions of the breast remains controversial. The expert panel focused on management recommendations for 3 of the most common infectious breast conditions, as very few evidence-based guidelines for the management of these conditions exist. Observations Clinicians should distinguish between infectious and noninfectious lactational mastitis (LM) because the former often requires interventions whereas the latter requires supportive care only. Patients with infectious LM often have thick fluid collections that are not amenable to aspiration and usually require a stab incision with drain placement (but no packing) to resolve the infection. Operative drainage is only required if the patient cannot tolerate an office procedure. If a phlegmon is present, antibiotics should be prescribed for at least 10 days. The diagnosis of granulomatous mastitis (GM) requires pathology confirmation with characteristic findings on core biopsy. Cystic neutrophilic granulomatous mastitis (CNGM) is a specific form of GM associated with a granulomatous reaction to Corynebacterium infection and should be empirically treated with doxycycline. For patients without findings characteristic of CNGM and no other associated bacterium identified, there is no role for empiric antibiotic use. Granulomatous mastitis cases often recur and can take up to 18 months to resolve. Patients who have GM cases with worsening symptoms should be treated with repeated intralesional steroid injections; surgical excision or repeated aspirations should be avoided. Cases refractory to intralesional steroid injection may require oral steroids or even advanced biologic agents such as methotrexate or azathioprine. Periductal mastitis with squamous metaplasia of lactiferous ducts (PDM-SMOLD) is a distinct entity from other periductal mastitis cases that can present with recurrent abscesses and should be treated with antibiotics and aspiration for fluid collections. Operative excision for PDM-SMOLD is required for those patients who present with a fistula or recurrent episodes typically using a radial incision to remove the diseased ducts within and below the nipple. Conclusions and Relevance Evidence-informed, consensus-, and expert opinion–based guidelines for the management of infectious and inflammatory conditions of the breast were developed. Clinicians can use these guidelines to appropriately manage these conditions for which clinical care often varied in the past.
The Impact of Antigen Presentation on BBB Disruption and Neuroinflammation
Maynes, Mark , Johnson, Aaron J. , Maynes, Mark A , Johnson, Aaron J.

Mayo Clinic

Physiology | March 31, 2026 | Volume: 41 | Issue: 6 | Pages: 630-643

10.1152/physiol.00041.2025 | PMID 41915408 Get It

Blood-brain barrier (BBB) disruption is a potentially deadly complication of numerous neurological diseases as diverse as cerebral malaria, dengue hemorrhagic fever, tauopathies, multiple sclerosis, schizophrenia, Parkinson’s disease, narcolepsy, and COVID-19. Neuroinflammation and immune cell infiltration are both drivers and consequences of BBB disruption. In this review, we will provide an overview of how brain-infiltrating T-cell responses engage the cellular components of the neurovascular unit (NVU), which regulates the BBB in preclinical models. This will provide context on how the immune system can contribute to vascular leakage and neuropathology in neurological diseases. We will discuss how discrete major histocompatibility complex (MHC) class I and class II molecules on NVU cell types govern T-cell entry, retention, and barrier disruption in neuroinflammatory diseases. Finally, we will summarize our current understanding of how discrete human leukocyte antigen (HLA) genes associate with specific neurological diseases characterized by neuroinflammation and BBB disruption.